Evaluate the Effect of Tirazamine on Primary Liver Cancer.
Status:
TERMINATED
Trial end date:
2023-11-20
Target enrollment:
Participant gender:
Summary
This Phase I/II trial aims to evaluate the pharmacokinetics, efficacy, and safety of tirapazamine administered via hepatic artery injection followed by TACE in patients with intermediate-stage HCC. The trial will compare the outcomes of TATE with standard TACE.